Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-3: LY3502970 versus oral semaglutide in adults with type 2 diabetes inadequately controlled on metformin
CTR20233528Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2023; status: completed.
02
Drugs
orforglipronsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20233528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233528.